Results 91 to 100 of about 1,436,145 (318)

Systemic T Cell Receptor Profiling Reveals Adaptive Immune Activation and Potential Immune Signatures of Diagnosis and Brain Atrophy in Epilepsy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epilepsy is increasingly associated with immune dysregulation and inflammation. The T cell receptor (TCR), a key mediator of adaptive immunity, shows repertoire alterations in various immune‐mediated diseases. The unique TCR sequence serves as a molecular barcode for T cells, and clonal expansion accompanied by reduced overall TCR ...
Yong‐Won Shin   +12 more
wiley   +1 more source

RETROSPECTIVE ANALYSIS OF PACKED RED BLOOD CELL TRANSFUSION IN TERTIARY CARE HOSPITALIN SOUTHERN INDIA [PDF]

open access: yesPerspectives In Medical Research, 2019
Introduction: Packed Red cells (Packed RBC) forms an important element in the treatment of various medical conditions. RBC transfusions are generally done to treat hemorrhage and also to enhance oxygen delivery to tissues. Transfusion of RBCs should be
Murali Krishna Bogi1, Sudhir Kumar Vujhini2, Kandukuri Mahesh Kumar1, Shanthi Bonagiri,3
doaj  

INF2‐Related Charcot–Marie–Tooth Disease in a Japanese Cohort: Genetic and Clinical Insights

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background INF2 mutations cause focal segmental glomerulosclerosis (FSGS) and Charcot–Marie–Tooth disease (CMT). Accurate genetic diagnosis is critical, as INF2‐related FSGS is typically resistant to immunotherapy yet rarely recurs after transplantation, and its associated neuropathy can mimic treatable immune‐mediated disorders such as ...
Chikashi Yano   +27 more
wiley   +1 more source

Expanding Hereditary Spastic Paraplegias Limits: Biallelic SPAST Variants in Cerebral Palsy Mimics

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hereditary spastic paraplegias (HSP) are rare neurodegenerative disorders marked by spasticity and lower limb weakness. The most common type, SPG4, is usually autosomal dominant and caused by SPAST gene variants, typically presenting as pure HSP.
Gregorio A. Nolasco   +18 more
wiley   +1 more source

Comparison of DNA extraction efficiency between two commercial kits on whole blood, swab, and plasma samples

open access: yesVietnam Journal of Science, Technology and Engineering
Whole blood, swab, and plasma samples are widely used in molecular biology testing in Vietnam. However, most DNA extraction kits currently in use are imported and rely on silica column technology, which can be challenging to integrate into automated or ...
Minh Quan Hoang   +7 more
doaj  

Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation [PDF]

open access: bronze, 2018
John Dou   +9 more
openalex   +1 more source

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 (SOD1) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss. Objective Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well ...
Mukesh Gautam   +6 more
wiley   +1 more source

P1611PRE-ANALYTICAL CONSIDERATIONS IN STUDYING CIRCULATING MICRORNA EXPRESSION: COMPARISON BETWEEN PAIRED EDTA PLASMA, EDTA WHOLE BLOOD AND PAXGENE BLOOD RNA TUBES [PDF]

open access: bronze, 2020
Veerle Wijtvliet   +7 more
openalex   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy